EUCTR2005-002501-23-IT进行中（未招募）不适用
A randomised,double-blind, placebo-controlled, multi-national, multi-centre, Phase III extension study to assess the long term efficacy, safety and carry-over effect of one of sublingual immunotherapy SLIT administered asllegen-based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- STALLERGENES
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy - A Phase II dose-finding study of atacicept in RARheumatoid arthritisEUCTR2006-004140-23-DEMerck Serono Int, a branch of Laboratoires Seron SA an affiliate of Merck KGaA, Darmstadt, Germany240
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, multi-national Phase II/III study of the safety and efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adult patients suffering from house dust mite allergic rhinitisEUCTR2007-001454-77-FRStallergenes S.A486
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multi-national Phase II/III study of the safety and efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adult patients suffering from house dust mite allergic rhinitisEUCTR2007-001454-77-CZStallergenes S.A486
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of one dose of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to children suffering from grass pollen rhinoconjunctivitisEUCTR2005-002502-34-DKStallergenes S.A.300
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multi-centre, multi-national Phase II / III follow-up study to assess long-term efficacy and safety of three different dose regimens of Oralgen® Grass Pollen in patients with grass pollen related allergic rhinoconjunctivitis (follow-up study to AB0602). - NAAllergic rhinoconjunctivitisEUCTR2007-002477-31-DEArtu Biologicals Europe B.V.560